Literature DB >> 10413694

Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration.

M Mauget-Faÿsse1, C Chiquet, D Milea, P Romestaing, J P Gérard, P Martin, F Koenig.   

Abstract

BACKGROUND/AIMS: Radiotherapy has been proposed as an alternative treatment for patients with subfoveal choroidal neovascularisation (CNV) that is untreatable according to macular photocoagulation study guidelines. This prospective study was designed to evaluate whether radiotherapy may affect the functional and anatomical outcome in a large cohort of patients affected by subfoveal CNV, with a follow up period up to 24 months.
METHODS: 212 patients (231 eyes) with newly diagnosed subfoveal CNV not amenable to laser therapy were included in this study. Two radiotherapy methods, the lateral beam technique (6 MV, 20 Gy in five fractions) and lateral arc therapy (25 MV, 16 to 20 Gy, in four or five fractions), were used. Comparisons of best corrected visual acuity (VA), fluorescein (FA) and indocyanine green (ICG) angiography, at inclusion and 6, 12, 18, and 24 months after radiotherapy were performed using univariate analysis.
RESULTS: A VA improvement of two or more lines was observed in 34% at 12 months, 31% at 18 months, and 32% of the eyes at 24 months. Paired comparisons of CNV areas in FA and ICG showed no significant change between baseline and each visit. However, 12 and 18 months after treatment, 47% of the eyes showed a decrease of 10% or more in CNV size both in ICG and FA. Radiation side effects included radiation retinopathy (eight eyes), optic neuropathy (four eyes), choroidal vasculopathy (five eyes), and branch retinal vein occlusion (three eyes).
CONCLUSION: Compared with the natural course of subfoveal CNV, the results of this prospective study suggest that radiotherapy could stabilise visual and anatomical outcome in selected cases.

Entities:  

Mesh:

Year:  1999        PMID: 10413694      PMCID: PMC1723150          DOI: 10.1136/bjo.83.8.923

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  26 in total

1.  Occult subretinal new vessels in age-related macular degeneration. Natural History and early laser treatment.

Authors:  G Soubrane; G Coscas; C Français; F Koenig
Journal:  Ophthalmology       Date:  1990-05       Impact factor: 12.079

2.  A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds.

Authors:  U Chakravarthy; T A Gardiner; D B Archer; C J Maguire
Journal:  Curr Eye Res       Date:  1989-04       Impact factor: 2.424

Review 3.  Late effects of radiation on the eye and ocular adnexa.

Authors:  K B Gordon; D H Char; R H Sagerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

4.  Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study.

Authors:  U Chakravarthy; R F Houston; D B Archer
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

5.  Radiation retinopathy after external-beam irradiation: analysis of time-dose factors.

Authors:  J T Parsons; F J Bova; C R Fitzgerald; W M Mendenhall; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-11-15       Impact factor: 7.038

6.  Contrast sensitivity, acuity, and the perception of 'real-world' targets.

Authors:  C Owsley; M E Sloane
Journal:  Br J Ophthalmol       Date:  1987-10       Impact factor: 4.638

7.  Recent trends in the registration of blindness and partial sight in Leicestershire.

Authors:  J R Thompson; L Du; A R Rosenthal
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

8.  Blind and partial sight registration in Avon.

Authors:  R H Grey; C J Burns-Cox; A Hughes
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

Review 9.  Age-related macular degeneration.

Authors:  N M Bressler; S B Bressler; S L Fine
Journal:  Surv Ophthalmol       Date:  1988 May-Jun       Impact factor: 6.048

10.  Radiation therapy for subfoveal choroidal neovascular membranes in age-related macular degeneration. A pilot study.

Authors:  G J Bergink; A F Deutman; J F van den Broek; W A van Daal; R W van der Maazen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-10       Impact factor: 3.117

View more
  8 in total

1.  A 5-year follow-up study for distance visual acuity after low dose radiation on subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  C Valmaggia; G Ries; P Ballinari
Journal:  Doc Ophthalmol       Date:  2001-11       Impact factor: 2.379

2.  Clinicopathological correlation of choroidal neovascularization after external beam radiotherapy in age-related macular degeneration.

Authors:  S Aisenbrey; B A Lafaut; S Reynders; P Szurman; S Grisanti; C Vanden Broecke; P Walter; K U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-22       Impact factor: 3.117

3.  Severe interferon associated retinopathy.

Authors:  K L Tu; J Bowyer; K Schofield; S Harding
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

Review 4.  Age related macular degeneration.

Authors:  Jennifer J Arnold; Wilson Heriot
Journal:  BMJ Clin Evid       Date:  2007-04-01

Review 5.  Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review.

Authors:  Stephanie R Rice; Matthew S J Katz; Minesh P Mehta
Journal:  Int J Part Ther       Date:  2016-03-24

Review 6.  Current and future treatment options for nonexudative and exudative age-related macular degeneration.

Authors:  Grant M Comer; Thomas A Ciulla; Mark H Criswell; Michael Tolentino
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study.

Authors:  P T Finger; Y P Gelman; A M Berson; A Szechter
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

8.  Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration.

Authors:  Kanako Itagaki; Tetsuju Sekiryu; Akihito Kasai; Yukinori Sugano; Masashi Ogasawara; Masaaki Saito
Journal:  BMC Ophthalmol       Date:  2020-07-10       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.